secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001193125-24-065416
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics announces accelerated Phase 2b/3 trial for bexotegrast and upsizes debt facility to $150M
--------------------------------------------------------------------------------

- BEACON-IPF trial implemented as pivotal, adaptive Phase 2b/3 design after EU and global health authority acceptance; expected to shorten late-stage development.
- Phase 3 enrollment begins immediately after Phase 2b completes; sample size increased by 90 patients to support registration.
- Oxford Finance debt facility upsized to $150M from $100M; initial $30M drawn, additional $70M contingent on bexotegrast milestones.
- Cash and equivalents of $495.7M as of Dec 31, 2023 plus new facility expected to fund operations through 2026.
- Bexotegrast is an oral dual-selective αvβ6/αvβ1 integrin inhibitor for IPF and PSC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524065416/0001193125-24-065416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524065416/d759675d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-065416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer